Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07181941 | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07184294 | Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer | recruiting | N/A | 50 | City of Hope Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07215494 | A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis | recruiting | N/A | 50 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07343934 | huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma | recruiting | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822789 | Chidamide in HR-AML | active not recruiting | — | 33 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01841723 | Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01920737 | A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03004287 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | active not recruiting | Phase 2 | 50 | University of ArkansasOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | active not recruiting | Phase 2 | 83 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | active not recruiting | Phase 2 | 340 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Sep 15, 2026 | clinicaltrials |
| NCT03516279 | Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | active not recruiting | Phase 2 | 40 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | active not recruiting | Phase 2 | 69 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | recruiting | Phase 3 | 200 | Novartis PharmaceuticalsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT04224974 | Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia(EASE) | recruiting | N/A | 266 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04497961 | A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide | active not recruiting | Phase 2 | 95 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04756401 | Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 8 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04996875 | (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | recruiting | Phase 2 | 140 | Cogent Biosciences, Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT05289687 | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | recruiting | Phase 2 | 20 | Eastern Cooperative Oncology GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05334823 | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | recruiting | Phase 2 | 100 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05554939 | Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05798897 | Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma(APOLLO) | recruiting | Phase 1 | 79 | Marker Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05998642 | Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | recruiting | Phase 2 | 30 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06002828 | Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | active not recruiting | — | 2,000 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06049134 | Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy | active not recruiting | Phase 4 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06182774 | Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma | recruiting | Phase 3 | 570 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06215118 | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | active not recruiting | Phase 1 | 100 | PfizerINDUSTRY | 3 | Sep 15, 2026 | clinicaltrials |
| NCT06303167 | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) | active not recruiting | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06308822 | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | suspended | N/A | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP(POLARIS-2) | recruiting | Phase 3 | 333 | Ascentage Pharma Group Inc.INDUSTRY | 16 | Sep 15, 2026 | clinicaltrials |
| NCT06466395 | A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias | recruiting | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | recruiting | Phase 3 | 440 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 31 | Sep 15, 2026 | clinicaltrials |
| NCT06647732 | Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | active not recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06810583 | A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia | recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06904482 | Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood | recruiting | Phase 2 | 36 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06976476 | Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia | recruiting | Phase 2 | 100 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 280 | Incyte CorporationINDUSTRY | 5 | Sep 15, 2026 | clinicaltrials |
| NCT07223190 | A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia(AUDAX) | not yet recruiting | Phase 3 | 560 | AmgenINDUSTRY | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07463976 | variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway(TITLE CLL) | not yet recruiting | — | 130 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07532473 | REal World MAIA UK OutcomEs(REMAKE) | not yet recruiting | — | 300 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07588594 | Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia | recruiting | N/A | 31 | Peking University People's HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07620275 | Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA | recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07723703 | Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML(BRAMLIE) | recruiting | Phase 1 | 54 | Amphista Therapeutics LtdINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07785180 | A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy | recruiting | — | 140 | Stemline Therapeutics, Inc.INDUSTRY | 11 | Sep 15, 2026 | clinicaltrials |
| NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial(PEARL RCT) | not yet recruiting | Phase 2 | 46 | University Health Network, TorontoOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00435864 | Natural Killer Index From Hematopoietic Stem Cell Graft | completed | N/A | 92 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00841724 | Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies(ITT 08-01) | completed | Phase 2 | 82 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT00863148 | Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)(Cloric) | completed | Phase 2 | 30 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01188174 | Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure(setric) | completed | Phase 2 | 26 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 16, 2026source: clinicaltrials